PARIS– On the occasion of Purple Day (March 26, 2022), an annual international event aimed at raising awareness of epilepsy, Angelini Pharma, international Italian pharmaceutical company, is committed to provide patients and healthcare professionals with innovative solutions improving the care of patients with epilepsy.
Epilepsy is a common neurological disorder that typically results in seizures of various types, with focal seizures being the most common one.1 The essential treatment goal of epilepsy therapy is seizure freedom.2
The global disease burden of epilepsy is high. 3,4 A diagnosis of epilepsy confers significant disability on the individual, including physical, psychological, and social issues that negatively impact self-esteem, family environment, relationships, leisure and working life. 3,5
Long-term outcomes for patients who have not responded to at least 2 antiepileptic drugs remain without significant improvement for more than 2 decades despite the availability of many new antiepileptic drugs. 6,7 Indeed, even today 40% of all patients with epilepsy do not achieve seizure freedom despite treatment with 2 different drugs.6,8
The probability of achieving the therapeutic goal of seizure freedom decreases significantly with each failed treatment. 6
Aware of the existence of an unmet medical need, Angelini Pharma is committed to make available a new anti-epileptic drug. The product received the Market Authorization from the European Medicines Agency (EMA) in March 2021 and many Early Access Program authorization across European countries, including in France. The product is already marketed in Germany, Austria, United Kingdom, Sweden, and Denmark.
